

L Darryl Quarles

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4829068/l-darryl-quarles-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

13,424
citations

61
h-index

113
g-index

175
ext. papers

14,762
ext. citations

7.6
avg. IF

6.65
L-index

#	Paper	IF	Citations
166	Novel Treatments from Inhibition of the Intestinal Sodium-Hydrogen Exchanger 3. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021 , 14, 411-420	2.5	2
165	Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development. <i>Current Medicinal Chemistry</i> , 2021 , 28, 1489-1507	4.3	27
164	Design and development of FGF-23 antagonists: Definition of the pharmacophore and initial structure-activity relationships probed by synthetic analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 29, 115877	3.4	1
163	Explaining Divergent Observations Regarding Osteocalcin/GPRC6A Endocrine Signaling. <i>Endocrinology</i> , 2021 , 162,	4.8	2
162	Role of GPRC6A in Regulating Hepatic Energy Metabolism in Mice. <i>Scientific Reports</i> , 2020 , 10, 7216	4.9	9
161	FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2020 , 138, 66-74	5.8	27
160	Humanized GPRC6A is a gain-of-function polymorphism in mice. <i>Scientific Reports</i> , 2020 , 10, 11143	4.9	5
159	Human GPRC6A Mediates Testosterone-Induced Mitogen-Activated Protein Kinases and mTORC1 Signaling in Prostate Cancer Cells. <i>Molecular Pharmacology</i> , 2019 , 95, 563-572	4.3	15
158	FGF-23 Deficiency Impairs Hippocampal-Dependent Cognitive Function. <i>ENeuro</i> , 2019 , 6,	3.9	13
157	Fibroblast growth factor 23 and Klotho co-dependent and independent functions. <i>Current Opinion in Nephrology and Hypertension</i> , 2019 , 28, 16-25	3.5	23
156	Molecular Control of Phosphorus Homeostasis and Precision Treatment of Hypophosphatemic Disorders. <i>Current Molecular Biology Reports</i> , 2019 , 5, 75-85	2	7
155	Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 69-80	12.7	19
154	Computationally identified novel agonists for GPRC6A. <i>PLoS ONE</i> , 2018 , 13, e0195980	3.7	12
153	FGF-23 Counter-Regulatory Hormone for Vitamin D Actions on Mineral Metabolism, Hemodynamics, and Innate Immunity 2018 , 871-884		
152	Role of Fibroblast Growth Factor-23 in Innate Immune Responses. <i>Frontiers in Endocrinology</i> , 2018 , 9, 320	5.7	21
151	Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial. <i>Kidney International Reports</i> , 2018 , 3, 897-904	4.1	9
150	Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II. <i>Scientific Reports</i> , 2018 , 8, 12398	4.9	29

149	Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis. <i>Journal of Clinical Investigation</i> , 2018 , 128, 157-174	15.9	32
148	Letter to the Editor: "Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH". <i>Endocrinology</i> , 2018 , 159, 3655-3656	4.8	
147	Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease. <i>Diagnostics</i> , 2018 , 8,	3.8	8
146	GPRC6A: Jack of all metabolism (or master of none). <i>Molecular Metabolism</i> , 2017 , 6, 185-193	8.8	46
145	CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 90	12.8	33
144	A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. <i>Science Signaling</i> , 2016 , 9, ra113	8.8	19
143	Joint mouse-human phenome-wide association to test gene function and disease risk. <i>Nature Communications</i> , 2016 , 7, 10464	17.4	91
142	FGF23 from bench to bedside. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 310, F1168-74	4.3	49
141	Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β -blocker treatment. <i>FASEB Journal</i> , 2016 , 30, 994-1001	0.9	27
140	Conditional Deletion of Fgfr1 in the Proximal and Distal Tubule Identifies Distinct Roles in Phosphate and Calcium Transport. <i>PLoS ONE</i> , 2016 , 11, e0147845	3.7	42
139	Multiple faces of fibroblast growth factor-23. <i>Current Opinion in Nephrology and Hypertension</i> , 2016 , 25, 333-42	3.5	20
138	The hypoxia-inducible factor-1 α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. <i>Bone Research</i> , 2016 , 4, 16011	13.3	40
137	Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. <i>Journal of Biological Chemistry</i> , 2015 , 290, 10447-59	5.4	38
136	Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. <i>Molecular Endocrinology</i> , 2015 , 29, 1759-73		43
135	Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1830-7	5.6	22
134	Association of body mass index with outcomes in patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2088-96	12.7	135
133	Bone Disorders in Chronic Kidney Disease 2014 , 476-487		
132	Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. <i>Annals of Internal Medicine</i> , 2013 , 159, 233-42	8	146

131	Novel bone endocrine networks integrating mineral and energy metabolism. <i>Current Osteoporosis Reports</i> , 2013 , 11, 391-9	5.4	42
130	A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease. <i>Seminars in Nephrology</i> , 2013 , 33, 130-42	4.8	20
129	Survival advantage in black versus white men with CKD: effect of estimated GFR and case mix. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 228-35	7.4	28
128	Management of Calcium and Bone Disease in Renal Patients 2013 , 3073-3086		
127	Calcium regulates FGF-23 expression in bone. <i>Endocrinology</i> , 2013 , 154, 4469-82	4.8	99
126	The role of fibroblast growth factor-23 in cardiorenal syndrome. <i>Nephron Clinical Practice</i> , 2013 , 123, 194-201		27
125	Chronic kidney disease and diabetes mellitus predict resistance to vitamin D replacement therapy. <i>American Journal of the Medical Sciences</i> , 2013 , 345, 314-320	2.2	7
124	Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new. <i>Journal of Clinical Investigation</i> , 2013 , 123, 542-3	15.9	10
123	Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. <i>Experimental Cell Research</i> , 2012 , 318, 1040-8	4.2	188
122	Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 38-46	6.3	75
121	Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. <i>Bioconjugate Chemistry</i> , 2012 , 23, 1507-12	6.3	56
120	Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. <i>Endocrinology</i> , 2012 , 153, 2062-9	4.8	73
119	GPRC6A mediates the effects of L-arginine on insulin secretion in mouse pancreatic islets. <i>Endocrinology</i> , 2012 , 153, 4608-15	4.8	57
118	A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. <i>PLoS ONE</i> , 2012 , 7, e44161	3.7	142
117	GPRC6A regulates prostate cancer progression. <i>Prostate</i> , 2012 , 72, 399-409	4.2	61
116	Regulation and function of the FGF23/klotho endocrine pathways. <i>Physiological Reviews</i> , 2012 , 92, 131-55	17.9	376
115	Assessment of 24,25(OH) ₂ D levels does not support FGF23-mediated catabolism of vitamin D metabolites. <i>Kidney International</i> , 2012 , 82, 1061-70	9.9	33
114	Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. <i>Nature Reviews Endocrinology</i> , 2012 , 8, 276-86	15.2	196

113	Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. <i>Journal of Cell Science</i> , 2012 , 125, 1945-57	5.3	74
112	Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. <i>Development (Cambridge)</i> , 2012 , 139, e1308-e1308	6.6	
111	Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. <i>Advances in Experimental Medicine and Biology</i> , 2012 , 728, 65-83	3.6	26
110	The bone and beyond: Dem bonesRare made for more than walking. <i>Nature Medicine</i> , 2011 , 17, 428-30	50.5	36
109	GPRC6A mediates responses to osteocalcin in cells in vitro and pancreas in vivo. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1680-3	6.3	168
108	Inducible expression of Runx2 results in multiorgan abnormalities in mice. <i>Journal of Cellular Biochemistry</i> , 2011 , 112, 653-65	4.7	16
107	Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E57-64	5.6	17
106	Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. <i>FASEB Journal</i> , 2011 , 25, 2551-62	0.9	189
105	Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. <i>FASEB Journal</i> , 2011 , 25, 2418-32	0.9	92
104	Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011 , 300, E508-17	6	79
103	FGF23/Klotho New Regulators of Vitamin D Metabolism 2011 , 747-761		1
102	Kif3a deficiency reverses the skeletal abnormalities in Pkd1 deficient mice by restoring the balance between osteogenesis and adipogenesis. <i>PLoS ONE</i> , 2010 , 5, e15240	3.7	33
101	Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 353-61	12.7	138
100	Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 110-6	6.9	118
99	Conditional disruption of Pkd1 in osteoblasts results in osteopenia due to direct impairment of bone formation. <i>Journal of Biological Chemistry</i> , 2010 , 285, 1177-87	5.4	47
98	GPRC6A mediates the non-genomic effects of steroids. <i>Journal of Biological Chemistry</i> , 2010 , 285, 39953-64	5.64	132
97	Impaired osteoblast function in GPRC6A null mice. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 1092-602	6.02	39
96	Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2010 , 56, 1108-16	7.4	14

95	ASARM mineralization hypothesis: a bridge too far?. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 692-4	4.3	7
94	Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?. <i>Nature Clinical Practice Nephrology</i> , 2009 , 5, 24-33		44
93	RUNX2 mutations in Chinese patients with cleidocranial dysplasia. <i>Mutagenesis</i> , 2009 , 24, 425-31	2.8	12
92	Dose-dependent effects of Runx2 on bone development. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1889-904	6.3	56
91	Bone Disorders in Chronic Kidney Disease 2009 , 487-498		1
90	Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?. <i>Nephrology News & Issues</i> , 2009 , 23, 33-4, 36-7		9
89	Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 658-64	6.9	119
88	Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. <i>Journal of Biological Chemistry</i> , 2008 , 283, 12624-34	5.4	52
87	FGFR3 and FGFR4 do not mediate renal effects of FGF23. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 2342-50	12.7	110
86	Parathyroid-specific interaction of the calcium-sensing receptor and G alpha q. <i>Kidney International</i> , 2008 , 74, 1548-56	9.9	14
85	Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs. <i>International Journal of Nephrology and Renovascular Disease</i> , 2008 , 1, 5-17	2.5	6
84	Inhibition of adipocyte differentiation by phytoestrogen genistein through a potential downregulation of extracellular signal-regulated kinases 1/2 activity. <i>Journal of Cellular Biochemistry</i> , 2008 , 104, 1853-64	4.7	45
83	Endocrine functions of bone in mineral metabolism regulation. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3820-8	15.9	340
82	GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. <i>PLoS ONE</i> , 2008 , 3, e3858	3.7	182
81	Management of Calcium and Bone Disease in Renal Patients 2008 , 2671-2679		
80	Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. <i>Seminars in Dialysis</i> , 2007 , 20, 302-8	2.5	88
79	How fibroblast growth factor 23 works. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 1637-47	12.7	312
78	Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. <i>Journal of Endocrinology</i> , 2007 , 192, 261-7	4.7	71

77	Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 2116-24	12.7	203
76	Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 293, E1636-44	6	74
75	Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. <i>Current Opinion in Nephrology and Hypertension</i> , 2007 , 16, 329-35	3.5	92
74	Hollow-Fiber versus Parallel-Plate Dialyzers in Continuous Arteriovenous Hemodialysis. <i>Seminars in Dialysis</i> , 2007 , 6, 229-231	2.5	2
73	Clinical Applications of Parathyroid Hormone Immunoassays in Patients with End Stage Renal Disease. <i>Seminars in Dialysis</i> , 2007 , 6, 305-311	2.5	
72	Osseous Complications of Renal Transplantation. <i>Seminars in Dialysis</i> , 2007 , 9, 353-359	2.5	3
71	RNA interference and its application in bone-related diseases. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 361, 817-21	3.4	9
70	Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified. <i>Nature Clinical Practice Nephrology</i> , 2006 , 2, 337-9		4
69	Pathogenic role of Fgf23 in Hyp mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006 , 291, E38-49	6	402
68	Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 1305-15	12.7	511
67	Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. <i>Nature Genetics</i> , 2006 , 38, 1310-5	36.3	937
66	Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005 , 288, E826-34	6	20
65	Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. <i>Kidney International</i> , 2005 , 68, S24-S28	9.9	11
64	Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. <i>Kidney International</i> , 2005 , S24-8	9.9	77
63	Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. <i>Kidney International</i> , 2005 , 67, 760-71	9.9	235
62	Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. <i>Journal of Cellular Biochemistry</i> , 2005 , 94, 307-16	4.7	81
61	Osteoblast calcium-sensing receptor has characteristics of ANF/7TM receptors. <i>Journal of Cellular Biochemistry</i> , 2005 , 95, 1081-92	4.7	19
60	Beta-arrestin- and G protein receptor kinase-mediated calcium-sensing receptor desensitization. <i>Molecular Endocrinology</i> , 2005 , 19, 1078-87		70

59	Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 1645-53	12.7	77
58	Identification of a novel extracellular cation-sensing G-protein-coupled receptor. <i>Journal of Biological Chemistry</i> , 2005 , 280, 40201-9	5.4	238
57	A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 862-9	6.3	67
56	Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34). <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 1661-70	6.3	15
55	FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003 , 285, E1-9	6	252
54	Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. <i>Current Opinion in Nephrology and Hypertension</i> , 2003 , 12, 349-55	3.5	44
53	Calcyclin mediates serum response element (SRE) activation by an osteoblastic extracellular cation-sensing mechanism. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 1825-33	6.3	18
52	Serum FGF23 levels in normal and disordered phosphorus homeostasis. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 1227-34	6.3	277
51	IRES-dependent translational control of Cbfa1/Runx2 expression. <i>Journal of Cellular Biochemistry</i> , 2003 , 88, 493-505	4.7	41
50	Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. <i>Journal of Nutritional Biochemistry</i> , 2003 , 14, 342-9	6.3	67
49	Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. <i>Journal of Biological Chemistry</i> , 2003 , 278, 37419-26	5.4	382
48	The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 575-83	12.7	208
47	Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. <i>Journal of Clinical Investigation</i> , 2003 , 111, 1029-37	15.9	54
46	Evidence for a bone-kidney axis regulating phosphate homeostasis. <i>Journal of Clinical Investigation</i> , 2003 , 112, 642-6	15.9	47
45	Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. <i>Journal of Clinical Investigation</i> , 2003 , 111, 1029-1037	15.9	126
44	Evidence for a bone-kidney axis regulating phosphate homeostasis. <i>Journal of Clinical Investigation</i> , 2003 , 112, 642-646	15.9	89
43	Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. <i>Journal of Biological Chemistry</i> , 2002 , 277, 3686-97	5.4	71
42	Calcium-sensing receptor activation of rho involves filamin and rho-guanine nucleotide exchange factor. <i>Endocrinology</i> , 2002 , 143, 3830-8	4.8	88

41	Hyperphosphatemia in end-stage renal disease. <i>Advances in Chronic Kidney Disease</i> , 2002 , 9, 184-92		15
40	Inhibition of MEPE cleavage by Phex. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 297, 38-45	3.4	95
39	Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. <i>Journal of Clinical Investigation</i> , 2002 , 109, 1361-1371	15.9	28
38	Effect of asymmetric dimethylarginine on osteoblastic differentiation. <i>Kidney International</i> , 2001 , 60, 1699-704	9.9	39
37	Cloning and characterization of the proximal murine Phex promoter. <i>Endocrinology</i> , 2001 , 142, 3987-95	4.8	24
36	Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 494-6	5.6	52
35	Rickets in cation-sensing receptor-deficient mice: an unexpected skeletal phenotype. <i>Endocrinology</i> , 2001 , 142, 3996-4005	4.8	88
34	Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. <i>Kidney International</i> , 2000 , 57, 282-92	9.9	68
33	Preventing bone loss after renal transplantation with bisphosphonates: we can... but should we?. <i>Kidney International</i> , 2000 , 57, 735-7	9.9	31
32	Aluminum is a weak agonist for the calcium-sensing receptor. <i>Kidney International</i> , 1999 , 55, 1750-8	9.9	31
31	Spectrum of disease in familial focal and segmental glomerulosclerosis. <i>Kidney International</i> , 1999 , 56, 1863-71	9.9	38
30	Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 2027-35	6.3	46
29	Failure to detect the extracellular calcium-sensing receptor (CasR) in human osteoblast cell lines. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 1310-9	6.3	57
28	Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 3860-6	5.6	17
27	A distinct cation-sensing mechanism in MC3T3-E1 osteoblasts functionally related to the calcium receptor. <i>Journal of Bone and Mineral Research</i> , 1997 , 12, 393-402	6.3	92
26	Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts. <i>Journal of Bone and Mineral Research</i> , 1997 , 12, 1009-17	6.3	91
25	Developmental regulation of osteocalcin expression in MC3T3-E1 osteoblasts: Minimal role of the proximal E-box cis-acting promoter elements. <i>Journal of Cellular Biochemistry</i> , 1997 , 65, 11-24	4.7	17
24	Differential regulation of receptor-stimulated cyclic adenosine monophosphate production by polyvalent cations in MC3T3-E1 osteoblasts. <i>Journal of Bone and Mineral Research</i> , 1996 , 11, 789-99	6.3	32

23	Calcitriol administration in end-stage renal disease: intravenous or oral?. <i>Pediatric Nephrology</i> , 1996 , 10, 331-6	3.2	8
22	Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. <i>Kidney International</i> , 1996 , 50, 1663-71	9.9	55
21	Oral versus intravenous calcitriol. <i>Current Opinion in Nephrology and Hypertension</i> , 1995 , 4, 307-312	3.5	5
20	Molecular to pharmacologic control of osteoblast proliferation and differentiation. <i>Journal of Cellular Biochemistry</i> , 1994 , 55, 310-20	4.7	62
19	Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. <i>Journal of Cellular Biochemistry</i> , 1994 , 56, 106-17	4.7	81
18	Role of serum in the developmental expression of alkaline phosphatase in MC3T3-E1 osteoblasts. <i>Journal of Cellular Physiology</i> , 1994 , 158, 467-75	7	37
17	Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. <i>Kidney International</i> , 1994 , 45, 1710-21	9.9	172
16	Mutations in the COL1A2 gene of type I collagen that result in nonlethal forms of osteogenesis imperfecta. <i>American Journal of Medical Genetics Part A</i> , 1993 , 45, 228-32		7
15	An experimental canine model of osteonecrosis: characterization of the repair process. <i>Journal of Orthopaedic Research</i> , 1993 , 11, 350-7	3.8	45
14	Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 683-92	6.3	723
13	Musculoskeletal complications after renal transplantation: pathogenesis and treatment. <i>American Journal of Kidney Diseases</i> , 1992 , 19, 99-120	7.4	118
12	Continuous arteriovenous hemodialysis: effect of dialyzer geometry. <i>Kidney International</i> , 1992 , 42, 448-51		12
11	Rapid loss of vertebral mineral density after renal transplantation. <i>New England Journal of Medicine</i> , 1991 , 325, 544-50	59.2	546
10	Aluminum-induced mitogenesis in MC3T3-E1 osteoblasts: potential mechanism underlying neoosteogenesis. <i>Endocrinology</i> , 1991 , 128, 3144-51	4.8	54
9	Uremic tumoral calcinosis: preliminary observations suggesting an association with aberrant vitamin D homeostasis. <i>American Journal of Kidney Diseases</i> , 1991 , 18, 706-10	7.4	29
8	Aluminum-induced neo-osteogenesis: a generalized process affecting trabecular networking in the axial skeleton. <i>Journal of Bone and Mineral Research</i> , 1990 , 5, 625-35	6.3	30
7	Equivalency of various methods for estimating osteoid seam width. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 671-7	6.3	9
6	Hemodialysis-associated subclavian vein stenosis. <i>Kidney International</i> , 1988 , 33, 1156-9	9.9	240

5	Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. <i>Kidney International</i> , 1988 , 34, 840-4	9.9	43
4	Late vascular complications of the subclavian dialysis catheter. <i>American Journal of Kidney Diseases</i> , 1986 , 7, 225-8	7.4	44
3	Staphylococcus aureus bacteremia in patients on chronic hemodialysis. <i>American Journal of Kidney Diseases</i> , 1985 , 6, 412-9	7.4	55
2	Small molecule FGF23 inhibitors increase serum phosphate and improve skeletal abnormalities in Hyp mice		1
1	Treatment Of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)640-650		3